Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. Sareum Holdings plc
  6. News
  7. Summary
    SAR   GB00B02RFS12

SAREUM HOLDINGS PLC

(SAR)
  Report
Delayed Quote. Delayed London Stock Exchange - 11/29 08:55:10 am
5.832 GBX   -1.15%
11/19SAREUM : Notice of AGM
PU
10/29Appointment of Joint Corporate Broker
PU
10/25SAREUM : Final Results
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Sareum : Reference to SRA737 Timeline at Cantor Conference

09/29/2021 | 06:22am EST

SAREUM HOLDINGS PLC

("Sareum" or "the Company")

Reference to Potential SRA737 Clinical Development Timeline in Sierra Oncology Investor Presentation at 2021 Cantor Virtual Global Healthcare Conference

Cambridge, UK, 29 September 2021 - Sareum Holdings plc (AIM: SAR), the specialist drug development company, notes that Sierra Oncology, the licence holder for SRA737 (a novel Chk1 inhibitor), presented at 21.00 BST on 28 September at the 2021 Cantor Virtual Global Healthcare Conference in a Fireside Chat. During this conference and included in a slide of recent and upcoming milestones, Sierra Oncology's CEO, Stephen Dilly, referred to the initiation of additional clinical studies with pipeline agents including SRA737 in other haematologic and solid tumour indications in the first half of 2022.

Specifically, reference was made to a potential role for SRA737 in combination studies in solid tumours, including pancreatic cancer, where patients have become resistant to PARP inhibitors.

In a previous discussion, noted by Sareum on 6 August 2021, of the rationale for in-licensing BET inhibitor AZD5153, now known as SRA515, from AstraZeneca, Sierra referred to possible pipeline expansion opportunities in other haematologic or solid tumour indications. These included potential combinations with SRA737, immune-oncology agents, PARP inhibitors and drugs with other mechanisms of action. Sierra has also noted that SRA515 has shown preclinical efficacy in combination with a diverse range of agents, and that synergy between SRA515 and a family of DNA damage response agents, known as ATR inhibitors, suggested potential utility in combination with SRA737.

SRA737 was discovered and initially developed by scientists at The Institute of Cancer Research in collaboration with Sareum, and with funding from Sareum and Cancer Research UK. SRA737 was licensed to Sierra in September 2016.

Sareum's CEO, Dr Tim Mitchell, commented:

"This timeline for the possible initiation of combination studies by Sierra including SRA737 in the first half of 2022 is very encouraging and would represent a significant advance in the development of the SRA737 programme. We look forward to further updates on the clinical development of SRA737, a molecule that has shown great promise in clinical trials and preclinical studies, particularly in combination with other types of cancer therapy,"

A recording of Sierra Oncology's fireside chat at the 2021 Cantor Virtual Global Healthcare Conference can be found at www.sierraoncology.com

For further information, please contact:

Sareum Holdings plc

Tim Mitchell, CEO

01223 497 700

Strand Hanson Limited (Nominated Adviser)

James Dance / James Bellman

020 7409 3494

Hybridan LLP (Nominated Broker)

Claire Noyce

020 3764 2341

MEDiSTRAVA Consulting (Financial PR)

Mark Swallow / David Dible

020 7638 9571

About Sareum

Sareum is a specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases. The Company aims to generate value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.

Sareum is advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases, including the 'cytokine storm' immune system overreaction to Covid-19 and other viral infections, (SDC-1801) and cancer immunotherapy (SDC-1802).

Sareum also has an economic interest in SRA737, a clinical-stage oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell replication and DNA damage repair mechanisms. Preliminary Phase 2 and comprehensive preclinical data suggest SRA737 may have broad application in combination with other oncology and immune-oncology drugs in genetically defined patients.

SRA737 was discovered and initially developed by scientists at The Institute of Cancer Research in collaboration with Sareum, and with funding from Sareum and Cancer Research UK. SRA737 was licensed by CRT Pioneer Fund (CPF) to Sierra Oncology Inc. Sierra continues to explore options that would enable the development of SRA737 to advance.

Sareum Holdings plc is listed on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit the Company's website at www.sareum.com

- Ends -

Disclaimer

Sareum Holdings plc published this content on 29 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 29 September 2021 10:21:00 UTC.


ę Publicnow 2021
All news about SAREUM HOLDINGS PLC
11/19SAREUM : Notice of AGM
PU
10/29Appointment of Joint Corporate Broker
PU
10/25SAREUM : Final Results
PU
10/25Sareum Holdings plc Reports Earnings Results for the Full Year Ended June 30, 2021
CI
10/21SAREUM : Notice of Results
PU
10/07SAREUM : US Patent Granted for SDC-1802 TYK2/JAK1 Inhibitor
PU
09/29SAREUM : Reference to SRA737 Timeline at Cantor Conference
PU
07/30SAREUM : Shares Jump 8% on Incoming Cancer Treatment Patent
MT
07/30SAREUM : Patent Notice of Allowance for SDC-1802
PU
07/21Sareum Holdings plc Provides Financial Guidance for Fiscal 2021
CI
More news
Financials
Sales 2021 0,17 M 0,23 M 0,23 M
Net income 2021 -1,63 M -2,18 M -2,18 M
Net Debt 2021 - - -
P/E ratio 2021 -118x
Yield 2021 -
Capitalization 199 M 265 M 265 M
Capi. / Sales 2021 1 170x
Capi. / Sales 2022 -
Nbr of Employees 6
Free-Float 95,5%
Chart SAREUM HOLDINGS PLC
Duration : Period :
Sareum Holdings plc Technical Analysis Chart | SAR | GB00B02RFS12 | MarketScreener
Technical analysis trends SAREUM HOLDINGS PLC
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 0
Last Close Price 0,06 
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
Timothy John Mitchell Chief Executive Officer & Executive Director
Stephen B. Parker Non-Executive Chairman
John Charles Reader Executive Director & Chief Scientific Officer
Clive Birch Independent Non-Executive Director
Michael John Owen Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
SAREUM HOLDINGS PLC143.30%265
GILEAD SCIENCES, INC.20.61%88 146
BIONTECH SE326.89%84 049
REGENERON PHARMACEUTICALS33.17%67 266
WUXI APPTEC CO., LTD.24.40%64 416
VERTEX PHARMACEUTICALS-22.32%46 678